We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Published in the Commonwealth of Australia Gazette No. GN 49, 14 December 2005
THERAPEUTIC GOODS ACT 1989
THERAPEUTIC GOODS REGULATIONS
I, PIO CESARIN, Director - Non-Prescription Medicines Branch, Therapeutic Goods Administration and delegate of the Secretary to the Department of Health and Ageing for the purposes of Section 42DF(1) of the Therapeutic Goods Act 1989, give notice that the restricted representations described in paragraph (a) below, have been approved for use in advertisements directed to consumers, for the products listed in paragraph (b) subject to the conditions outlined in paragraph (c):
- Representations to the effect that advertisements to consumers for the goods described in paragraph (b) may refer to:
- "Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life";
- medicines entered in the Australian Register of Therapeutic Goods containing vitamin D; and
- the advertised medicines may only contain a maximum recommended daily dose of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D for the intended consumers to which advertising is directed.
Dated this 1st day of December 2005
PIO CESARIN
Delegate of the Secretary to the Department of Health and Ageing